DaVita (LTS:0I7E) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0I7E DaVita Inc LTS:0I7E
87 GF Score
Price $175.37
GF Value $195.87
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is DaVita SpecialCharges?

Special Charges only applies to banks.

LTS:0I7E
87GF Score
DaVita Inc LTS:0I7E
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is DaVita (LTS:0I7E) Overvalued in 2026?

Based on GuruFocus' analysis, DaVita stock appears to be undervalued. The current stock price of $175.37 is trading 10.5% below its estimated GF Value™ of $195.87. GuruFocus considers DaVita to be Modestly Undervalued.

Key valuation signals for LTS:0I7E:

  • SpecialCharges:
  • GF Value™: $195.87 vs. price of $175.37 (10.5% below fair value)
  • GF Score™: 87/100 with 6 warning signs

No single metric tells the full story. See the LTS:0I7E stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DaVita Business Description

Address 2000 16th Street, Denver, CO, USA, 80202
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
87GF Score

Get the complete analysis for LTS:0I7E

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$175.37
Price
$195.87
GF Value